Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna Inc

Moderna Says Dual Variant COVID-19 Booster With Beta is Better Effective Against Omicron Than Current Jab

Moderna Inc (NASDAQ:MRNA) said a COVID-19 booster designed to target the Beta variant and the original coronavirus generated a better immune response against several virus variants, including Omicron. Moderna said the results were a good sign for the company's plans for future shots targeting two COVID-19 variants. The company said the bivalent…

Benzinga

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report

Japan's health ministry panel authorized a plan to approve Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine, which is set to be the fourth such vaccine to be approved in Japan. It will be available for first and second shots with an interval of three weeks. The Novavax product is a recombinant protein vaccine that uses…

Benzinga

Britain Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Britain's medicines regulator approved the use of Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine in children between six and 11 years. The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required safety, quality, and effectiveness standards. Read Next: Why Did Moderna Recall Thousands Of COVID-19…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Did Moderna Recall Thousands Of COVID-19 Vaccine Doses In Europe?

Moderna Inc (NASDAQ:MRNA) recalled 764,900 doses of its COVID-19 vaccine made by its Spanish contract manufacturer Rovi after a foreign body contaminated a vial. No safety issues have been identified, Moderna said, about the lots distributed in Norway, Poland, Portugal, Spain, and Sweden in January. Japanese authorities last year suspended the use of…

Benzinga

Moderna recalls thousands of COVID vaccine doses in Europe

Moderna Inc said on Friday it was recalling 764,900 doses of its COVID-19 vaccine made by its contract manufacturer Rovi after a vial was found contaminated by a foreign body.

Reuters

See Why COVAX, African Union Refuse To Buy More Moderna's COVID-19 Vaccine

COVAX, the global project to share COVID-19 vaccines, and the African Union have declined options to buy additional doses of Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine despite the low immunization rate as developing nations struggle to allocate supplies. The African Union and Covax decided not to obtain more of the vaccine as developing nations struggle…

Benzinga

Why Moderna Shares Are Trading Lower

Moderna Inc (NASDAQ: MRNA) shares are trading lower Tuesday following reports indicating that both the African Union and COVAX Consortium have declined to purchase the company's COVID-19 vaccine doses.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

FDA clears way for millions to get additional COVID-19 boosters

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 4.67% at $181.16 after the company received FDA approval for Emergency Use Authorization for a second booster dose of its COVID-19 vaccine.

Benzinga

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

The FDA has approved a second round of the Moderna Inc (NASDAQ:

Benzinga

FDA clears way for millions to get additional COVID-19 boosters

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

Tribune News Service

3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China

China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyzing Moderna Inc's Short Interest

Moderna Inc's (NASDAQ:MRNA) short percent of float has risen 7.66% since its last report. The company recently reported that it has 17.61 million shares sold short, which is 5.06% of all regular shares that are available for trading.

Benzinga

Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6

Moderna Inc (NASDAQ:MRNA) has announced interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273) in children six months to under six years. The interim analysis showed that two 25 μg doses of mRNA-1273 in participants 6 months to under six years met the primary endpoint with robust neutralizing antibody…

Benzinga

Why Moderna Shares Are Trading Higher Today

Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments.

Benzinga

Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

5 Cheap Value Stocks to Add to Your Portfolio

Despite the latest federal interest rate hikes, undervalued stocks with impressive financials are expected to deliver solid returns in the coming months. So, we think it could be wise to scoop up quality stocks Moderna (MRNA), Bayer (BAYRY), Henkel (HENKY), AGCO (AGCO), and Penske Automotive (PAG), which are currently trading…

Businessweek

The Future of Boosters Is Somewhere Between Unnecessary and Urgent

Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.

Benzinga

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Benzinga

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

Benzinga

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 7.0% at $158.42. The company announced today it has reached an agreement with Japan to supply an additional 70 million doses of its COVID-19 booster vaccine.

Benzinga

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.